Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Last updated: 3 September 2026

Clear filter
682 clinical trials found
Clinical trials

SNDX-5613-0700

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation (NCT04065399)

Currently recruiting

SNDX-5613-0708

Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A [KMT2A/MLL], Nucleophosmin 1 [NPM1], and Nucleoporin 98 [NUP98] Genes (NCT06226571)

Currently recruiting

SNDX-5613-0710

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation [REVEAL-ND NPM1] (NCT07211958)

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
Currently recruiting

SNIPER

Stereotactic ablative body radiation therapy with Nodal Irradiation for ProstatE canceR (ACTRN12625000259448)

Currently recruiting

SNV1521

A PHASE 1, OPEN-LABEL DOSE ESCALATION AND EXPANSION STUDY OF SNV1521 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS (NCT06220864)

Currently recruiting

SOCRATES

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (ACTRN12621001444875p)

Currently recruiting

SODa-BIC

SODa-BIC: Sodium Bicarbonate For Metabolic Acidosis in the Intensive Care Unit, A Multicentre, Randomised, Double-Blind Clinical Trial (NCT05697770)

No longer recruiting

SPK-8011-8016-LTFU

A Multi-Center Evaluation of the Long-Term Safety and Efficacy of Spark-sponsored Gene Therapies in Males with Hemophilia A (NCT03432520)

Currently recruiting

SPYRAL AFFIRM

The SPYRAL AFFIRM Global Clinical Study of Renal Denervation with the Symplicity Spyral Renal Denervation System in Subjects with Uncontrolled Hypertension (SPYRAL AFFIRM) (NCT05198674)

Currently recruiting

STALL HFpEF 2

Randomized trial of medical therapy versus conduction system pacing with AV node ablation in persistent atrial fibrillation [AF] and heart failure with preserved ejection fraction (ACTRN12625000466448)

Currently recruiting

STAR AF

STRATEGIES FOR CATHETER ABLATION OF PERSISTENT ATRIAL FIBRILLATION: A RANDOMIZED, COMPARATIVE STUDY (STAR AF 3) (NCT04428944)

Currently recruiting

STAR-0215-302

A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE (NCT07204938)

This is an extension study for patients with Hereditary Angioedema who participated in the STAR-0215-301 study.
Currently recruiting

STARLIGHT

A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-related liver disease (NCT06613698)

A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 70 years with alcohol-related liver disease.
Currently recruiting

STARWARS

Salvage sTereotactic Ablative radiotherapy for Recurrent prostate cancer With Androgen suppression and Rectal Spacer (ACTRN12625000224426)

Currently recruiting

STOP

The Silicosis Treatment Of Prednisolone (STOP) Study: A pilot study assessing the effectiveness of Prednisolone on respiratory function in adults with silicosis. (ACTRN12623000622606)

Currently recruiting

STOP-GAP

A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) (NCT02821013)

Currently recruiting

STOP-MS

Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STOP-MS) (ACTN12621001502820)

We have selected two potential anti-Epstein-Barr virus therapies (spironolactone and famciclovir) to test in an innovative multi-stage, multi-arm trial in order to identify the best treatment for progressive MS. Treatments will be compared to dummy-treatment.
Currently recruiting

STOP-MSU

A phase II randomised, placebo-controlled, investigator-driven trial of tranexamic acid within 2 hours of intracerebral haemorrhage (NCT03385928)

Currently recruiting

STOPit

Study of tofacitinib for the treatment of chronic pouchitis (STOPit) (ACTRN12621000173897)

Currently recruiting

StrateGIST 3 / GSK300383

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 [GSK6042981] versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors [GIST] after Imatinib Therapy [StrateGIST 3] (NCT07218926)

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib.
Currently recruiting
28 29 30 31 32